Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5971412 | 0.83 | NOD1 (0.46) | NOD1MMP2MMP9FOLH1NAALAD2 | |
| SCHEMBL29362117 | 0.82 | NOD1 (0.50) | NOD1MMP2MMP9FOLH1NAALAD2 | |
| SCHEMBL12983544 | 0.82 | NOD1 (0.50) | NOD1MMP2MMP9FOLH1NAALAD2 | |
| SCHEMBL21034479 | 0.82 | FAAH (0.41) | NOD1MMP2MMP9CAPN1ALDH1A1 | |
| SCHEMBL15846337 | 0.82 | FOLH1 (0.64) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL15846336 | 0.82 | FOLH1 (0.64) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL5971089 | 0.82 | NOD1 (0.48) | NOD1MMP2MMP9FOLH1CAPN1 | |
| SCHEMBL5970398 | 0.82 | NOD1 (0.45) | NOD1MMP2MMP9FOLH1 | |
| SCHEMBL15451409 | 0.81 | NOD1 (0.50) | NOD1MMP2MMP9FOLH1NAALAD2 | |
| SCHEMBL16620664 | 0.81 | NOD1 (0.61) | NOD1MMP2MMP9FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10834951-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2020-11-17 | — | — | US | claimed |
| EP-3057449-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2018-02-28 | — | — | EP | claimed |
| US-20170258122-A1 | Organic Compounds | GIVAUDAN S.A. (CH) | 2017-09-14 | — | — | US | claimed |
| EP-3057449-A1 | ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2016-08-24 | — | — | EP | claimed |
| WO-2015050535-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2015-04-09 | — | — | WO | claimed |
| WO-2015049294-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2015-04-09 | — | — | WO | claimed |
| US-10834951-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2020-11-17 | — | — | US | disclosed |
| CN-105592721-B | Organic compounds | 奇华顿股份有限公司 | 2020-03-17 | — | — | CN | disclosed |
| EP-3057449-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-20170258122-A1 | Organic Compounds | GIVAUDAN S.A. (CH) | 2017-09-14 | — | — | US | disclosed |
| EP-3057449-A1 | ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015050535-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015049294-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10834951-B2 | Organic compounds | CBR3, C9, AOC2 | NOD1 1614/4885MMP2 4040/4885MMP9 3961/4885 |
| US-20170258122-A1 | Organic Compounds | CBR3, C9, AOC2 | NOD1 1614/4885MMP2 4040/4885MMP9 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.